NCT03461042View on ClinicalTrials.gov

The Study of Combination Use of Melatonin Receptor Agonist for Dose Reduction or Interruptions of Benzodiazepine (BZD) and Non-BZD Hypnotics on Chronic Insomnia

PHASE4CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 6, 2018

Primary Completion Date

July 31, 2019

Study Completion Date

March 16, 2020

Conditions
Chronic Insomnia
Interventions
DRUG

Ramelteon 8mg

Ramelteon 8mg once daily before bedtime for 12 weeks since informed consent

DRUG

Placebo

Placebo capsule once daily before bedtime for 12 weeks since informed consent

Trial Locations (1)

151-0053

Yoyogi Sleep Disorder Clinic, Foundation of Sleep and Health Science, Shibuya-ku

All Listed Sponsors
collaborator

Yoyogi Sleep Disorder Clinic, Foundation of Sleep and Health Science

UNKNOWN

lead

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

OTHER

NCT03461042 - The Study of Combination Use of Melatonin Receptor Agonist for Dose Reduction or Interruptions of Benzodiazepine (BZD) and Non-BZD Hypnotics on Chronic Insomnia | Biotech Hunter | Biotech Hunter